Monoclonal Antibodies in Cancer Therapy doi:10.1016/0952-7915(90)90035-F单克隆抗体癌症治疗血管内皮生长因子抗肿瘤活性同位素标记放射性核素免疫系统免疫原性摘要:临床肿瘤与癌症研究:英文版Yu-TingQin-YuWANG
Monoclonal antibodies finding a place in cancer therapy After waiting in the wings for more than 10 years, monoclonal antibodies are finally finding a place on the clinical stage for the treatment of various can... S Henahan - 《Inpharma Weekly》 被引量: 0发表: 1998年 Send in the clones...
COLE ET AL.: 'Monoclonal Antibodies and Cancer Therapy', 1985, ALAN R. LISS page 77Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, 1985, p. 77.Cole, et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., 1985, 77-96....
A monoclonal antibody (Mab) is made by a population of identical immune cells that are the progeny of a unique parent cell. Mab therapy of cancer is a form of immunotherapyin which a patient is...doi:10.1007/978-3-642-27841-9_7071-3Ingegerd Hellstrom...
(Biochemistry) an antibody, produced by a single clone of cells grown in culture, that is both pure and specific and is capable of proliferating indefinitely to produce unlimited quantities of identical antibodies: used in diagnosis, therapy, and biotechnology ...
The “magic bullet” era of targeted cancer therapy began with the United States Food and Drug Administration approval of rituximab for the treatment of B-cell lymphoma in the late fall of 1997. Since then, several additional anticancer antibody products have received regulatory approval, including ...
However, administration of mAbs carries the risk of immune reactions such as acute anaphylaxis, serum sickness and the generation of antibodies. In addition, there are numerous adverse effects of mAbs that are related to their specific targets, including infections and cancer, autoimmune disease, and...
utilizing the immune system to eliminate cancer holds great potential. Although various immunotherapeutic approaches have been shown to enhance the immune system’s ability to modulate cancer, therapeutic antibodies that target regulatory pathways in T-cells to enhance antitumor immune responses, have attra...
[3]Robinson MP, Ke N, Lobstein J, Peterson C, Szkodny A, Mansell TJ, et al. Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria. Nat Commun 2015; 6: 8072. [4]You M,Yang Y,Zhong C,Chen FT,Wang X,Jia TR, et al.Efficient mAb production in CHO ...
- 《Clinical Cancer Research》 被引量: 257发表: 2013年 Trial Watch: Monoclonal antibodies in cancer therapy - OncoImmunology - Volume 1, Issue 1 Since the advent of hybridoma technology, dating back to 1975, monoclonal antibodies have become an irreplaceable diagnostic and therapeutic tool for a ...